These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38983866)

  • 41. Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas.
    Gao C; Zhuang J; Zhou C; Ma K; Zhao M; Liu C; Liu L; Li H; Feng F; Sun C
    J Cell Physiol; 2019 May; 234(5):6519-6528. PubMed ID: 30246311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GADD45B predicts lung squamous cell carcinoma survival and impacts immune infiltration, and T cell exhaustion.
    Lv Y; Liu Z; Xiong K; Duan H; Yang J; Liao P
    Autoimmunity; 2023 Dec; 56(1):2209706. PubMed ID: 37165780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Exploring the Role of PCDHGB4 in the Occurrence of Lung Squamous Cell Carcinoma Based on Bioinformatics Analysis].
    Lu R; Abuduhailili X; Li Y; Ning J; Feng Y
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):199-215. PubMed ID: 38590195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minichromosome maintenance gene family: potential therapeutic targets and prognostic biomarkers for lung squamous cell carcinoma.
    Yang X; Wang C; Nie H; Zhou J; He X; Ou C
    Aging (Albany NY); 2022 Nov; 14(22):9167-9185. PubMed ID: 36445337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.
    Wang L; Liu Z; Liu L; Guo C; Jiao D; Li L; Zhao J; Han X; Sun Y
    J Cell Mol Med; 2021 Aug; 25(15):7559-7574. PubMed ID: 34288370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
    Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
    Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
    Gong L; Liu Q; Jia M; Sun X
    Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.
    Huang G; Huang Q; Xie Z; Zhou H; Cao J; Shi L; Yang M
    Cancer Biomark; 2019; 26(3):239-247. PubMed ID: 31524143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes.
    Pu J; Teng Z; Yang W; Zhu P; Zhang T; Zhang D; Wang B; Hu Z; Song Q
    Carcinogenesis; 2023 May; 44(2):143-152. PubMed ID: 36455238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma.
    Xia L; Lin H; Cao H; Lian J
    BMC Cancer; 2024 May; 24(1):561. PubMed ID: 38711034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.